Poor clinical outcomes and immunoevasive contexture in CD161⁺CD8⁺ T cells barren human pancreatic cancer

Abstract

CD161⁺CD8⁺ T cells exhibit elevated levels of both cytotoxic and immune-checkpoint molecules, indicating as a potential and attractive target for immunotherapy. The tumor-infiltrating CD161⁺CD8⁺ T cell is a valuable and promising predictor for survival and therapeutic response to adjuvant chemotherapy in PDAC. Further research is warranted to validate its role in the risk stratification and optimization of therapeutic strategies.